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Sir,
We read with considerable interest the review by RE Coleman
(2008) discussing the latest clinical aspects of bisphosphonates
(BP) use and their side effects.
Coleman reports that 75% of BP-related osteonecrosis of the jaw
(ONJ) occurs following a dental extraction or jaw surgery. This
might be true, however, in a case–control study that we recently
published, in which the percentage of breast cancer patients under
zolendronic acid (ZA) treatment who developed ONJ after having
experienced tooth extraction was found to be 50% (Kyrgidis et al,
2008). In this study, patients who experienced tooth extraction
were reported to have an at least 16 times higher risk of developing
ONJ. Nonetheless, tooth extraction and alveolar surgery may not
be the only important clinical factor for ONJ development. In our
study, we also report the use of dentures to account for an almost
five-fold higher risk for ONJ development. A recent paper
(Landesberg et al, 2008) provides evidence that the oral mucosa
can actually be defective. We hypothesised that potentially ill-fit
dentures could cause breaches to the defective underlying mucosa,
thereby providing an entry point to the bone for oral flora
(Kyrgidis and Vahtsevanos, 2008; Kyrgidis et al, 2008).
Coleman notes that the reported frequency of ONJ varies
considerably between o1 and 410% among different populations.
This fact has also been emphasised by other authors, especially in
regard to the Greek and US population (Raje et al, 2008). We have
suggested that it could be an issue of differential susceptibility to
ONJ in the Greek population (Kyrgidis and Andreadis, 2008),
although careful pretreatment, dental assessment and avoidance of
invasive dental procedures, as suggested by the author (Coleman,
2008), could partly account for this difference. The latter hypothesis
is supported by the evidence we provide (Kyrgidis et al, 2008) that
tooth extractions may amplify the risk for ONJ development.
In accordance with Coleman, we believe that prospective
research is definitely required to assess potential risk factors,
effect modifiers and confounders. In this regard, we currently
carry out a prospective cohort study with breast, prostate cancer
and multiple myeloma patients receiving BP treatment (ZA and
ibandronate). In this study, the type, dose and duration of
treatment is monitored. Results will be published when the study is
concluded (Kyrgidis et al, 2008).
Coleman has suggested that until solid evidence is available,
patients receiving BP should have regular inspection of the mouth,
undergo dental check-ups every 6–12 months and avoid invasive
dental surgery unless no alternative is available (Coleman, 2008).
Our study provides substantial evidence supporting that suggestion,
at the same time raising the current ASCO level of evidence linking
ONJ to tooth extractions from V to III. We further suggest, on the
basis of evidence (Kyrgidis et al,2 0 0 8 ) ,t h a ta d d i t i o n a ld e n t a la n d
medical attention should be paid to BP patients using removable
dentition to avoid mucosal breaches caused by dentures.
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